Pharmacotherapy of Candida bloodstream infections: new treatment options, new era.
Evolving medical practices and the widespread use of fluconazole have clearly affected the spectrum of invasive mycoses now encountered by clinicians. The proportion of infections due to azole-resistant Candida species and invasive moulds has increased steadily over the last decade, creating a need for broad-spectrum antifungal agents with safety profiles similar to fluconazole. Efforts to address this need have lead to the reformulation of older, broad-spectrum antifungals and the development of new agents with enhanced activity against non-C. albicans and Aspergillus species. This review highlights pharmacodynamic, pharmacokinetic, safety and cost considerations for current and emerging antifungal therapies to be used in the treatment of bloodstream candidiasis.
Lewis
Russell E
RE
University of Houston College of Pharmacy, Texas Medical Center, Houston, TX 77030, USA. rLewis@uh.edu
D000935:Antifungal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D002175:Candida / Q000187:drug effects*; D002177:Candidiasis / Q000097:blood / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D017850:Economics, Pharmaceutical; D006207:Half-Life; D006801:Humans; D007408:Intestinal Absorption; D008657:Metabolic Clearance Rate; D008826:Microbial Sensitivity Tests; D016896:Treatment Outcome
D000935:Antifungal Agents